Close Menu

The story has been corrected to reflect that the name of one of the checkpoint inhibitor therapies is PD-L1 and the name of MioDx's immunosequencing platform is called ClonoMap. Our apologies for the errors. 

NEW YORK (360Dx) – Cancer biomarker firm MioDx on Thursday said it has exclusively licensed technologies from the University of California, San Francisco related to monitoring patient response to immunotherapies.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.